By harnessing the power of mass spectrometry-based proteomics to identify cancer-causing proteins that undergo a specific post-translational modification called auto-palmitoylation, Tasca is uniquely positioned to utilize previously unknown binding pockets to develop novel therapies for difficult-to-treat cancers.
Tasca’s lead program, CP-383, is being developed to treat patients with tumors harboring a specific genetic profile and is expected to enter clinical trials in 2025.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 55 Spinelli Pl, Cambridge,massachusetts 02138,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.tascatx.com/
- HQ
- Cambridge, Massachusetts
Tasca Therapeutics Questions
Tasca Therapeutics's website is https://www.tascatx.com/
Tasca Therapeutics's LinkedIn profile is https://www.linkedin.com/company/tasca-therapeutics
Tasca Therapeutics has
11 employees.
View email and phone details for 11
employees at Tasca Therapeutics.
Tasca Therapeutics's industry is
Biotechnology Research
Tasca Therapeutics's top competitors are
Light Horse Therapeutics,
Epivax, Inc.,
Synolo Therapeutics,
Verimmune,
Kymera Therapeutics,
Triana Biomedicines,
Stylus Medicine,
Cure Ventures,
Photys Therapeutics,
Hyku Biosciences.
Tasca Therapeutics's categories are Biotechnology Research
Tasca Therapeutics's founding year is 2021
